Fig Therapeutics

Fig Therapeutics is a biotechnology company focused on the discovery and development of novel therapies targeting lysosomal biology and the mTOR pathway. Founded by leading experts in cellular metabolism, the company aims to address neurodegenerative and rare genetic diseases by restoring cellular proteostasis and autophagy. Their platform leverages advanced insights into how the lysosome functions as a metabolic signaling hub to identify small molecule modulators of disease-relevant pathways. Fig Therapeutics is currently advancing a pipeline of pre-clinical programs designed to treat conditions characterized by lysosomal dysfunction, such as Parkinson's disease. The company's research is centered on translating fundamental discoveries in nutrient sensing and organelle biology into transformative medicines.